Celgene to acquire Pharmion

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

In patients with small cell lung cancer, Lambert-Eaton myasthenic syndrome leads to muscle weakness and can be discovered with no-cost testing such as anti-VGCC antibody testing.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Tim Cortese

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

Genomic Assay Yields Strong Predictive Accuracy in HER2+ Breast Cancer

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.

Intervention Increases Palliative Cancer Care Consultations/Lowers EOL Care

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.

An algorithm-based palliative care intervention provides a scalable implementation strategy to increase referrals in the community oncology setting.

3 Things You Should Know About Recognizing LEMS in Patients With SCLC

Related Content

ONCOLOGY Staff

March 12th 2025

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

In patients with small cell lung cancer, Lambert-Eaton myasthenic syndrome leads to muscle weakness and can be discovered with no-cost testing such as anti-VGCC antibody testing.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Tim Cortese

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

Genomic Assay Yields Strong Predictive Accuracy in HER2+ Breast Cancer

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Intervention Increases Palliative Cancer Care Consultations/Lowers EOL Care

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.